The rapid evolution of the GLP-1 market is reshaping how pharmaceutical manufacturers and digital health platforms work together.

The recent agreement between Novo Nordisk and Hims & Hers is a striking example – turning a legal dispute over compounded GLP-1s into a distribution partnership.

In an interview with MedCity News, Managing Partner Michael Abrams shared his thoughts on the deal, noting that it could be beneficial for both parties.

[Novo Nordisk] needs more customers, faster, and Hims needs to be out of the compounding game, at least on this product, and needs to find another way to make money.

In a market where competition from Eli Lilly and Company is intensifying, getting patients started on a drug today is one of the best ways to secure long-term market share.

Read the full story at medcitynews.com.